Who Supplies Prednisolone to India from SOUTH AFRICA

To import finished pharmaceutical formulations containing Prednisolone into India, an Import Registration and License from the Central Drugs Standard Control Organization (CDSCO) is mandatory. The application process involves submitting Form 44 for permission to import or manufacture a new drug, along with Form 12 for a license to import drugs for examination, test, or analysis. The CDSCO evaluates the safety, efficacy, and quality data of the product before granting approval. The registration process typically takes several months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049099, compliance with the Drugs and Cosmetics Act, 1940, and the associated rules is required.

Imported pharmaceutical formulations containing Prednisolone must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors ensures that the imported products meet the required quality standards before clearance.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing Prednisolone, must obtain import registration and licenses to prevent the sale of unapproved or illegal medicines in the Indian market. This regulation aims to streamline the import process and ensure that all imported pharmaceutical products meet the necessary quality, safety, and efficacy standards.

India imports finished Prednisolone formulations to meet the demand for specific dosage forms and branded products not manufactured domestically. The market size for Prednisolone formulations in India is substantial, with a total export market of $96.0 million across 755 exporters to 182 countries. This indicates a significant domestic demand for Prednisolone formulations, which is partially met through imports.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% is applied on the BCD, resulting in a total duty of 11%. Integrated Goods and Services Tax (IGST) is applicable at 12%, calculated on the sum of the CIF (Cost, Insurance, and Freight) value plus the total duty. There are no exemptions or preferential duty rates for imports from South Africa.

India sources finished Prednisolone formulations from South Africa due to the availability of specific dosage forms and branded products not produced domestically. South African manufacturers may offer competitive pricing and quality, making them attractive suppliers. Other suppliers include China, Germany, and the United States, each with their own advantages in terms of product offerings and pricing. South Africa's share in the Indian market for Prednisolone formulations is growing, reflecting its competitive position.

India imports finished Prednisolone formulations from South Africa to access specific dosage forms and branded products not manufactured domestically. South African manufacturers may offer competitive pricing and quality, making them attractive suppliers. The availability of unique formulations and the need to meet domestic demand contribute to the decision to source from South Africa.

When compared to other origins such as China, the European Union, and the United States, South Africa offers competitive advantages in terms of product quality, pricing, and regulatory compliance. South African manufacturers may provide unique formulations and dosage forms not available from other suppliers, enhancing their appeal to Indian importers.

Indian importers face potential risks when sourcing finished Prednisolone formulations from South Africa, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for supply chain disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts and inventory capacity.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits of manufacturing facilities, to ensure compliance with quality standards and regulatory requirements.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Apply for registration under Form 40/41 for the import of drugs.
3. 3Drug Import License: Secure a license to import drugs for examination, test, or analysis.
4. 4No Objection Certificate (NOC): Obtain an NOC from the CDSCO if required.
5. 5Customs Broker: Engage a licensed customs broker to facilitate import clearance.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Confirming compliance with Indian Pharmacopoeia standards.
2. 2Certificate of Pharmaceutical Product (CoPP): Indicating GMP compliance.
3. 3Good Manufacturing Practice (GMP) Certificate: Issued by the relevant authority.
4. 4Drug Master File (DMF): Providing detailed information on the manufacturing process.